Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.

Clin Cancer Res 2016 Dec 24;22(23):5839-5850. Epub 2016 May 24.

Department of Oncology, University of Calgary, Calgary, Alberta, Canada.

Purpose: In addition to their direct cytopathic effects, oncolytic viruses are capable of priming antitumor immune responses. However, strategies to enhance the immunotherapeutic potential of these agents are lacking. Here, we investigated the ability of the multi-tyrosine kinase inhibitor and first-line metastatic renal cell carcinoma (RCC) agent, sunitinib, to augment the antitumor immune response generated by oncolytic reovirus.

Experimental Design: In vitro, oncolysis and chemokine production were assessed in a panel of human and murine RCC cell lines after exposure to reovirus, sunitinib, or their combination. In vivo, the RENCA syngeneic murine model of RCC was employed to determine therapeutic and tumor-specific immune responses after treatment with reovirus (intratumoral), sunitinib, or their combination. Parallel investigations employing the KLN205 syngeneic murine model of lung squamous cell carcinoma (NSCLC) were conducted for further validation.

Results: Reovirus-mediated oncolysis and chemokine production was observed following RCC infection. Reovirus monotherapy reduced tumor burden and was capable of generating a systemic adaptive antitumor immune response evidenced by increased numbers of tumor-specific CD8 IFNγ-producing cells. Coadministration of sunitinib with reovirus further reduced tumor burden resulting in improved survival, decreased accumulation of immune suppressor cells, and the establishment of protective immunity upon tumor rechallenge. Similar results were observed for KLN205 tumor-bearing mice, highlighting the potential broad applicability of this approach.

Conclusions: The ability to repurpose sunitinib for augmentation of reovirus' immunotherapeutic efficacy positions this novel combination therapy as an attractive strategy ready for clinical testing against a range of histologies, including RCC and NSCLC. Clin Cancer Res; 22(23); 5839-50. ©2016 AACR.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0143DOI Listing
December 2016

Publication Analysis

Top Keywords

cell carcinoma
12
antitumor immune
12
tumor burden
8
immune responses
8
immune response
8
chemokine production
8
syngeneic murine
8
reduced tumor
8
sunitinib combination
8
renal cell
8
oncolysis chemokine
8
murine model
8
immune
5
sunitinib
5
reovirus
5
rcc
5
reovirus monotherapy
4
rcc infection
4
infection reovirus
4
monotherapy reduced
4

Similar Publications